FDA approves Wynzora cream for plaque psoriasis
Click Here to Manage Email Alerts
Wynzora cream, MC2 Therapeutics’ plaque psoriasis treatment, has been approved by the FDA for once-daily use in adult patients, according to a press release.
Wynzora cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) is based on PAD technology, which enables stability of both drugs in an aqueous formulation.
The approval was based on phase 3 clinical trial data that found Wynzora showed at least a two-grade improvement in Physician Global Assessment to clear or almost clear after 8 weeks of treatment.
In addition, more patients reached a minimum four-point improvement in Peak Pruritus Numerical Rating Scale with Wynzora cream than vehicle.
“Wynzora cream is a novel topical treatment for plaque psoriasis which offers a unique combination of high efficacy, favorable safety and excellent treatment convenience in a single product,” Linda Stein Gold, MD, director of dermatology clinical research at Henry Ford Health System in Detroit and lead principal investigator of the study, said in the release.
Read more about
Click Here to Manage Email Alerts